Skip to main content

Advanced Melanoma IOV-MEL-301 (TILVANCE-301)

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.

Kevin Kim
Kevin Kim
Principal investigator
View Profile

Email Us to Enroll

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?